Novelix Pharmaceuticals Reports Nil Deviation in Preferential Issue Fund Utilization
Novelix Pharmaceuticals Ltd 路 Others (Uncategorized) 路 12 Nov 2026, 12:59 am
Novelix Pharmaceuticals Reports Nil Deviation in Preferential Issue Fund Utilization Novelix Pharmaceuticals Limited submitted its Statement of Deviation or Variation for the quarter ended 30th Sep'26, reporting zero deviation in the utilization of proceeds raised via preferential issue on 9th Jul'26. The company deployed Rs. 506.25 lakhs entirely toward long-term funding, working capital, and general corporate purposes. In a separate tranche of Rs. 684.00 lakhs, funds were utilized across land development (Rs. 104.00 lakhs utilized out of Rs. 188.00 lakhs allocated), land lease deposit (Rs. 100.00 lakhs), consumables (Rs. 100.00 lakhs), pre-operative expenses (Rs. 125.00 lakhs), technology transfer fees to GMBU Germany (Rs. 75.00 lakhs), quality control equipment (Rs. 61.00 lakhs), and travel expenses (Rs. 35.00 lakhs).
Original exchange filing (PDF)
More announcements from Novelix Pharmaceuticals Ltd
- Submission of Intimation of Corporate office opening. 路 18 Nov 2026
- Submission of Supply agreement intimation. 路 13 Nov 2026
- Submission of intimation of change in Designation of Director. 路 12 Nov 2026
- Submission of unaudited financial results for the quarter and half year ended September, 2026. 路 12 Nov 2026
- Submission of outcome of the Board Meeting. 路 12 Nov 2026
- Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve unaudited standalone .... 路 11 Nov 2026
- Attached 路 03 Oct 2026
- Attached 路 02 Oct 2026
